Abstract:Methods for the targeted integration of genes in mammalian genomes suffer from low programmability, low efficiencies or low specificities. Here we show that phage-assisted continuous evolution enhances prime-editing-assisted site-specific integrase gene editing (PASSIGE), which couples the programmability of prime editing with the ability of recombinases to precisely integrate large DNA cargoes exceeding 10 kilobases. Evolved and engineered Bxb1 recombinase variants (evoBxb1 and eeBxb1) mediated up to 60% donor integration (3.2-fold that of wild-type Bxb1) in human cell lines with pre-installed recombinase landing sites. In single-transfection experiments at safe-harbour and therapeutically relevant sites, PASSIGE with eeBxb1 led to an average targeted-gene-integration efficiencies of 23% (4.2-fold that of wild-type Bxb1). Notably, integration efficiencies exceeded 30% at multiple sites in primary human fibroblasts. PASSIGE with evoBxb1 or eeBxb1 outperformed PASTE (for 'programmable addition via site-specific targeting elements', a method that uses prime editors fused to recombinases) on average by 9.1-fold and 16-fold, respectively. PASSIGE with continuously evolved recombinases is an unusually efficient method for the targeted integration of genes in mammalian cells.

What problem does this paper attempt to address?

The paper aims to address the issue of efficient, site-specific integration of large genes in mammalian cells. Existing gene targeting integration methods suffer from low programmability, low efficiency, or poor specificity. The authors optimized the Bxb1 recombinase through continuous evolution techniques (PACE and PANCE) and developed a technology called PASSIGE (Prime Editing-Assisted Site-Specific Integrase Gene Editing). This technology combines the programmability of guided editing with the ability of recombinases to precisely integrate large DNA cargo, enabling the efficient integration of genes larger than 10 kilobases into specific sites in mammalian cells. Specifically, the main contributions of the paper include: 1. **Improved Integration Efficiency**: By optimizing the Bxb1 recombinase through continuous evolution techniques, the efficiency of gene integration was significantly increased. The optimized recombinase variants (such as evoBxb1 and eeBxb1) achieved integration efficiencies of up to 60% in human cell lines, which is 3.2 times higher than the wild-type Bxb1. 2. **Broad Applicability**: The PASSIGE technology demonstrated high integration efficiency at multiple safe harbor and therapeutically relevant sites, particularly in primary human fibroblasts, where the integration efficiency exceeded 30%. 3. **Comparison with Existing Technologies**: PASSIGE and its optimized versions (evoPASSIGE and eePASSIGE) showed significantly higher integration efficiencies at various genomic sites compared to the existing PASTE technology, with improvements of 9.1-fold and 16-fold, respectively. In summary, the paper presents an efficient gene integration method, providing a new tool for gene therapy and functional genomics research.

Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing